The
development of drug delivery systems using nanoparticles as
carriers for small and large therapeutic molecules remains a rapidly
growing area of research. The advantages of using proteins to prepare
nanoparticles for drug delivery applications include their abundance
in natural sources, biocompatibility, biodegradability, easy synthesis
process, and cost-effectiveness. In contrast to several particulate
systems like nanoparticles from metallic and inorganic/synthetic sources,
the protein nanoparticles do not have limitations such as potential
toxicity, large size, accumulation, or rapid clearance from the body.
In addition, protein-based nanoparticles offer the opportunity for
surface modification by conjugation of other protein and carbohydrate
ligands. This enables targeted delivery to the desired tissue and
organ, which further reduces systemic toxicity. The use of protein
nanoparticles for such applications could therefore prove to be a
better alternative to maneuver and improve the pharmacokinetic and
pharmacodynamic properties of the various types of drug molecules.
In this review, while focusing on the properties of a few proteins
such as the silk protein fibroin, we attempt to provide an overview
of the existing protein-based nanoparticles. We discuss various methods
for the synthesis of this class of nanoparticles. The review brings
forth some of the factors that are important for the design of this
class of nanoparticles and highlights the applications of the nanoparticles
obtained from these proteins.
Background:The causal relationship between tubulin acetylation and microtubule stability has remained poorly understood. Results: Pharmacological inhibition of HDAC6 increased HDAC6 binding to microtubules, enhanced microtubule stability, and suppressed dynamics. Conclusion: Increased binding of HDAC6, rather than acetylation per se, causes microtubule stability. Significance: The study indicates a MAP-like function of HDAC6 that extends beyond its tubulin deacetylase function.
Haematospermia (or haemospermia) is a distressing symptom in sexually active men. In most cases, it is caused by non-specific inflammation of the prostate and seminal vesicles. In a small percentage of men, however, it may be a manifestation of genito-urinary or systemic malignancy, in particular prostate cancer. The purpose of this review is to explain the causes and management of patients with haematospermia.
The widespread problem of bacterial resistance towards existing drugs and the paucity of effective drugs for the treatment of bacterial infections have prompted the scientific community to think about novel strategies for discovering new classes of antibacterial drugs. Target-based screening of inhibitory molecules has emerged as an important alternative for the development of potent antibacterials. FtsZ is a prokaryotic cytoskeleton protein, which plays an important role in bacterial cell division. It forms a highly dynamic Z-ring at the centre of the cell and recruits other accessory proteins, which are involved in bacterial cytokinesis. Here, we discuss the assembly dynamics of FtsZ and the key features that place it among the novel antibacterial drug targets. The recent progress in finding the inhibitors of functional properties of FtsZ and its interactions with other proteins, which has been enabled by advanced screening methods and structure-based design, are presented herein. Although there are significant challenges in the development of this new class of antibacterial drugs, nonetheless the therapeutic potential of FtsZ as a drug target is motivating researchers to find lead molecules with enhanced efficacy and reduced toxicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.